Stockscreener 앱 받기
4.43
0.34%
0.010
전일 마감가:
$4.42
열려 있는:
$4.39
하루 거래량:
128.67K
Relative Volume:
0.13
시가총액:
$652.30M
수익:
$170.28M
순이익/손실:
$-225.25M
주가수익비율:
-3.3308
EPS:
-1.33
순현금흐름:
$-167.02M
1주 성능:
-20.52%
1개월 성능:
-2.53%
6개월 성능:
+27.08%
1년 성능:
+5.09%
1일 변동 폭
$4.29
$4.45
1주일 범위
$4.29
$5.788
52주 변동 폭
$2.28
$6.70
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
명칭
Adaptive Biotechnologies Corp
전화
206-659-0067
주소
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ADPT | 4.44 | 652.30M | 170.28M | -225.25M | -167.02M | -1.33 |
| VRTX | 447.41 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.11 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.03 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.03 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.69 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-12-21 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Underperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 재확인 | BTIG Research | Buy |
| 2022-02-16 | 재확인 | BofA Securities | Buy |
| 2022-02-16 | 재확인 | Goldman | Neutral |
| 2022-02-16 | 재확인 | JP Morgan | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-03-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-03 | 개시 | Goldman | Buy |
| 2019-07-23 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | BofA/Merrill | Buy |
| 2019-07-22 | 개시 | Cowen | Outperform |
| 2019-07-22 | 개시 | Goldman | Neutral |
| 2019-07-22 | 개시 | Guggenheim | Buy |
| 2019-07-22 | 개시 | William Blair | Outperform |
모두보기
Adaptive Biotechnologies Corp 주식(ADPT)의 최신 뉴스
Adaptive Biotechnologies (FRA:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey - Defense World
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares - Investing.com India
Adaptive Biotechnologies Corp: Is ADPT Stock Worth Buying? - Stocks Register
William Blair Has Bullish Forecast for ADPT FY2024 Earnings - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Decrease in Short Interest - MarketBeat
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know - Yahoo Finance
Rubric Capital Management LP's Strategic Acquisition in Adaptive Biotechnologies Corp - GuruFocus.com
Matrix Capital Management Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 12.7% Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00 - MarketBeat
ADPT (Adaptive Biotechnologies) Cash From Other Investing A - GuruFocus.com
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Earnings call: Adaptive Biotechnologies posts robust MRD revenue growth - Investing.com
ARK Investment Management LLC Buys 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highl - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ... - Yahoo Finance
ADPT stock touches 52-week high at $5.81 amid biotech rally By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $5.81 amid biotech rally - Investing.com Canada
Adaptive Biotechnologies earnings beat by $0.07, revenue topped estimates - Investing.com
Adaptive Biotechnologies : Q3 2024 Earnings Presentation - Marketscreener.com
Adaptive Biotechnologies: Q3 Earnings Snapshot - CT Insider
ADPTAdaptive Biotechnologies Corporation Latest Stock News & Market Updates - StockTitan
Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings: Revenue S - GuruFocus.com
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results - Yahoo Finance
Medicare expands coverage for MRD test in lymphoma - Investing.com
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma - Yahoo Finance
ADPT (Adaptive Biotechnologies) Total Stockholders Equity : $241.6 Mil (As of Jun. 2024) - GuruFocus.com
Earnings To Watch: Adaptive Biotechnologies Corp (ADPT) Reports Q3 2024 Result - GuruFocus.com
Sumitomo Mitsui Trust Group's Strategic Acquisition in Adaptive Biotechnologies - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition in Adaptive Biotechno - GuruFocus.com
November 2024's Top US Penny Stocks With Growth Potential - Yahoo Finance
ADPT (Adaptive Biotechnologies) Cyclically Adjusted Book pe - GuruFocus.com
Adaptive Biotechnologies (ADPT) Scheduled to Post Earnings on Thursday - MarketBeat
Cancer Immunotherapy Global Market 2024 To Reach $175.39Billion By 2028 At Rate Of 12.1% - EIN News
Cancer Immunotherapy Global Market 2024 To Reach $175.39 Billion By 2028 At Rate Of 12.1% - EIN News
ADPT (Adaptive Biotechnologies) PE Ratio : At Loss (As of Oct. 30, 2024) - GuruFocus.com
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Receives $7.00 Consensus Price Target from Analysts - MarketBeat
Perhaps timely catching Adaptive Biotechnologies Corp (ADPT) would be a good idea - SETE News
Adaptive Biotechnologies Corp [ADPT] Stock sold by Insider Taylor Stacy L for $0.12 million - Knox Daily
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap UpStill a Buy? - MarketBeat
Stock Surge: Adaptive Biotechnologies Corp (ADPT) Closes at 4.94, Marking a 0.61 Increase/Decrease - The Dwinnex
Should investors be concerned about Adaptive Biotechnologies Corp (ADPT)? - US Post News
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap DownTime to Sell? - MarketBeat
Adaptive Biotechnologies Corp (ADPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):